Repositioning of clinically approved drug Bazi Bushen capsule for treatment of Alzheimer's disease using network pharma-cology approach and in vitro experimental validation
10.3867/j.issn.1000-3002.2023.z1.024
- Author:
Tongxing WANG
1
,
2
;
Meng CHEN
;
Bin HOU
;
Junqing LIANG
;
Cong WEI
;
Zhenhua JIA
Author Information
1. National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine,Shijia-zhuang 050035,China
2. Hebei Yiling Pharmaceu-tical Research Institute,Key Laboratory of State Administration of TCM(Cardio-Cerebral Vessel Collateral Diseases),Shijiazhuang 050035,China
- Keywords:
Drug repositioning;
Bazi Bushen capsule;
Network pharmacology;
Alzheimer's disease;
Mechanism of action
- From:
Chinese Journal of Pharmacology and Toxicology
2023;37(z1):22-23
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the new indications and key mechanism of Bazi Bushen capsule(BZBS)by network pharmacology and in vitro experiment.METHODS The potential tar-get profiles of the components of BZBS were pre-dicted.Subsequently,new indications for BZBS were predicted by disease ontology(DO)enrich-ment analysis and initially validated by GO and KEGG pathway enrichment analysis.Further-more,the therapeutic target of BZBS acting on AD signaling pathway were identified by intersec-tion analysis.Two Alzheimer's disease(AD)cell models,BV-2 and SH-SY5Y,were used to pre-liminarily verify the anti-AD efficacy and mecha-nism of BZBS in vitro.RESULTS In total,1499 non-repeated ingredients were obtained from 16 herbs in BZBS formula,and 1320 BZBS targets with high confidence were predicted.Disease enrichment results strongly suggested that BZBS formula has the potential to be used in the treat-ment of AD.In vitro experiments showed that BZ-BS could significantly reduce the release of TNF-α and IL-6 and the expression of COX-2 and PSEN1 in A β 25-35-induced BV-2 cells.BZBS reduced the apoptosis rate of A β 25-35 induced SH-SY5Y cells,significantly increased mitochon-drial membrane potential,reduced the expres-sion of Caspase3 active fragment and PSEN1,and increased the expression of IDE.CONCLU-SIONS BZBS formula has a potential use in the treatment of AD,which is achieved through regu-lation of ERK1/2,NF-κB signaling pathways,and GSK-3β/β-catenin signaling pathway.Further-more,the network pharmacology technology is a feasible drug repurposing strategy to reposition new clinical use of approved TCM and explore the mechanism of action.The study lays a foun-dation for the subsequent in-depth study of BZBS in the treatment of AD and provides a basis for its application in the clinical treatment of AD.
